Status: Recruiting
Intrathecal PD-1/VEGF Bispecific Antibody Plus Pemetrexed for Leptomeningeal Metastasis
Leptomeningeal metastasis, characterized by tumor cells infiltrating and proliferating in the subarachnoid space, represents a distinct pattern of central nervous system involvement and is a fatal complication of malignant tumors. This phase I/II study is to evaluate the recommended dose, safety, feasibility, and therapeutic response of intrathecal PD-1/VEGF bispecific antibody plus pemetrexed in patients with leptomeningeal metastasis.
Participants needed: 34
Trial details
Phase: Phase 1, Phase 2Age: 21-75Biological sex: AllType: InterventionalSponsor: Guangzhou Medical UniversityUpdated: May 20, 2025Locations: 1
Eligibility criteria
Histologically or cytologically confirmed diagnosis of solid tumors;Cerebrospina... [+2]
Any evidence of nervous system failure, including severe encephalopathy, grade 3... [+5]